ライフサイエンスコーパス: RIF

1 RIF binding was monitored using absorbance at 525 nm to

2 RIF counts overall correlated with dose rates across all

3 RIF-1 belongs to the small and poorly explored class of

4 RPL 2.37, range across lesions 1.26-22.03); RIF, PZA, and LZD showed moderate yet suboptimal lesion

5 The RPH enzyme is a RIF-inactivating phosphotransferase and represents a new

6 together with RIF (period 1), 4 weeks after RIF discontinuation (period 2), and after the RAL dose r

7 tially then 400 mg twice daily 4 weeks after RIF discontinuation.

8 ions to RMP may recover its efficacy against RIF(R) TB.

9 that acts via the mod-1 receptor in AIY and RIF interneurons and is antagonized by pigment-dispersin

10 strated drug-drug interaction between FA and RIF, which lowered FA levels to a degree that could infl

11 erial subpopulations are similar for INH and RIF treatment: mostly intracellular with extracellular b

12 ity and specificity for detection of MTB and RIF and INH drug resistance and may be an important tool

13 ty and specificity for detection of MTB, and RIF and INH drug resistance and may be an important tool

14 rial tissues taken from patients with RM and RIF.

15 ve (including rifampin [RIF] susceptible and RIF resistant), and nontuberculosis mycobacterial materi

16 itivity for detection of M. tuberculosis and RIF resistance, including in AFB-negative sputum, and ha

17 teric conflicts that essentially prevent any RIF binding.

18 are of immediate public health importance as RIF+ABZ are registered drugs and thus immediately implem

19 middle domain, which is involved in binding RIF.

20 ChIP) assays revealed that PXR activation by RIF disrupted enhancer-promoter communication and prompt

21 sis of interactions of RMP with three common RIF(R) mutant RNAPs suggests that modifications to RMP m

22 Interference with these fluid lipid domains (RIFs) perturbs overall lipid homeostasis and affects mem

23 ly small decreases in AUC0-12 and C12 during RIF coadministration, warranting further evaluation in p

24 hat occurs before formation of the ternary E-RIF-NADPH complex.

25 uit memory selection mechanisms, eliminating RIF.

26 ), which is found upstream of genes encoding RIF-inactivating enzymes from a diverse collection of ac

27 Using this method, we compared excess RIFs side by side in recipients of (177)Lu-DOTATOC or (1

28 l biopsies (n = 115) from women experiencing RIF and healthy controls.

29 An FA/RIF pharmacokinetic interaction has not previously been

30 label randomized study, we evaluated oral FA/RIF vs standard-of-care (SOC) intravenous antibiotics fo

31 Fourteen subjects were randomized 1:1 to FA/RIF or SOC.

32 ere obtained for 6 subjects randomized to FA/RIF.

33 ory (PCIT) and the regulatory impact factor (RIF), in which we included the estimated genomic breedin

34 ating sulfonolipid rosette-inducing factors (RIFs) to recapitulate the full bioactivity of live Algor

35 f women with recurrent implantation failure (RIF) and recurrent miscarriages (RM).

36 Recurrent implantation failure (RIF) is a condition whereby couples fail to achieve preg

37 rriage (RM), recurrent implantation failure (RIF) or fertile controls.

38 ic membrane regions with increased fluidity (RIFs).

39 he average number of radiation-induced foci (RIF) per cell increased over the first 3 h after radionu

40 (gamma-H2AX) to mark radiation-induced foci (RIFs).

41 ibility) for first-line agents was 95.0% for RIF (132/139), 98.2% for INH (111/113), and 98.6% for EM

42 ng to side effects were 35% for INH, 21% for RIF, and 10% for RPT/INH.

43 7.1%/97.1%, 98.2%/97.8%, and 96.5%/97.5% for RIF and 94.4%/96.4%, 95.4%/98.8%, and 94.9%/97.6% for IN

44 0.3%/98.5%, 90.3%/98.5%, and 92.0%/98.5% for RIF resistance detection and 89.1%/99.4%, 89.1%/99.4%, a

45 V2 and Nipro to Hain V1 was demonstrated for RIF and INH resistance detection in isolates and sputum

46 The double dose of RAL overcompensated for RIF induction, but the standard dose was associated with

47 Sensitivity for RIF-resistant M. tuberculosis in AFB-negative sputum was

48 Sensitivity and specificity for RIF resistance compared to phenotypic DST was 90% (9/10

49 Sensitivity and specificity for RIF resistance compared with phenotypic DST were 90% (9/

50 Overall microarray specificity for RIF, INH, and EMB combined was 97.2% (384/395).

51 positive and negative predictive values for RIF, INH, and EMB combined were 84.9% and 98.3%, respect

52 kely resulting in the decreased affinity for RIFs.

53 ates that this retrieval-induced forgetting (RIF) phenomenon reflects inhibitory mechanisms called in

54 cipants showed Retrieval-Induced Forgetting (RIF), reflecting the suppression of competing informatio

55 This rectangular ion funnel (RIF) was initially evaluated by ion simulations, fabrica

56 ed a heretofore unknown RIF resistance gene, RIF phosphotransferase (rph).

57 RPH orthologs are widespread and found in RIF-sensitive bacteria, including Bacillus cereus and th

58 nregulated and upregulated, respectively, in RIF-treated ShP51 cells, and these regulations were conf

59 INH/RIF coadministration was associated with limited changes

60 ameters of EFV400 without (PK1) and with INH/RIF following 4 (PK2) and 12 (PK3) weeks of coadministra

61 77)Lu-PSMA, 22) to quantify blood lymphocyte RIFs and blood activity concentrations at various time p

62 Significantly more RIFs were found in (177)Lu-DOTATOC recipients by compari

63 MTB/RIF C(T) is a poor surrogate of load in extrapulmonary s

64 rator assuming expanded use of GeneXpert MTB/RIF ('Xpert') for TB diagnosis.

65 ult subjects, including sputum GeneXpert MTB/RIF (GeneXpert)-confirmed TB patients (n = 138), sputum

66 GeneXpert MTB/RIF (Xpert), a novel, semiautomated TB nucleic-acid ampl

67 with tuberculosis through the GeneXpert MTB/RIF assay to identify patients with multidrug-resistant

68 available diagnostics, and the GeneXpert MTB/RIF assay when available before inclusion.

69 ed the reporter phage assay to GeneXpert MTB/RIF for detection of M. tuberculosis and rifampin (RIF)

70 t comparative study of the new GeneXpert MTB/RIF Ultra (Xpert Ultra) for TBM diagnosis suggested incr

71 Health Organization recommends GeneXpert MTB/RIF Ultra (Xpert Ultra), a fully automated PCR assay, as

72 city were compared to those of GeneXpert MTB/RIF with an M. tuberculosis culture as the reference sta

73 GeneXpert MTB/RIF-confirmed patients with rifampicin-susceptible tuber

74 (LAM) test (Alere TB LAM) and GeneXpert-MTB/RIF (Xpert) are useful for the diagnosis of TB.

75 ming the current gold-standard GeneXpert-MTB/RIF.

76 ty (TTP; a surrogate of bacterial load), MTB/RIF TB-specific and internal positive control (IPC)-spec

77 in days) was the strongest associate of MTB/RIF positivity in each fluid.

78 ssociated with a decreased likelihood of MTB/RIF-positivity in pulmonary specimens but an increased l

79 compartments, is the main determinant of MTB/RIF-positivity rather than PCR inhibition.

80 f smear microscopy and Xpert MTB/RIF (or MTB/RIF Ultra) as comparators is critical to allow broader c

81 We assessed the utility of Xpert((R)) MTB/RIF (GeneXpert) as a screening tool for medical admissio

82 ar microscopy group vs 2 [0.25-3] in the MTB/RIF group; p=0.85) or 6 months (1 [0-3] vs 1 [0-3]; p=0.

83 (182 culture positive) and 744 to Xpert MTB/RIF (185 culture positive).

84 cterial culture, smear microscopy, Xpert MTB/RIF (Cepheid Inc.), tuberculin skin test (TST), and ches

85 pecimens were also tested with the Xpert MTB/RIF (GXP) assay.

86 Inclusion of smear microscopy and Xpert MTB/RIF (or MTB/RIF Ultra) as comparators is critical to all

87 were tested for tuberculosis with Xpert MTB/RIF (Xpert group) versus sputum smear microscopy (sputum

88 The Xpert MTB/RIF (Xpert) assay is a rapid nucleic acid amplification

89 The Xpert MTB/RIF (Xpert) assay is becoming a principal screening tool

90 The Xpert MTB/RIF (Xpert) assay offers rapid and accurate diagnosis of

91 The Xpert MTB/RIF (Xpert) assay permits rapid near-patient detection o

92 Performing Xpert MTB/RIF (Xpert) at point of care is feasible, even when perf

93 Xpert MTB/RIF (Xpert) detects rifampicin-resistant tuberculosis (R

94 TB by sputum smear microscopy and Xpert MTB/RIF (Xpert) from February 2012 to June 2017.

95 ompared the diagnostic accuracy of Xpert MTB/RIF (Xpert) with microscopy for detection of pulmonary t

96 ore sensitive diagnostics, such as Xpert MTB/RIF (Xpert), is still limited by costs.

97 sis in HIV-infected children using Xpert MTB/RIF (Xpert).

98 ibility testing (DST), BD MAX, and Xpert MTB/RIF (Xpert).

99 tibility testing (DST), BD MAX and Xpert MTB/RIF (Xpert).

100 hree testing strategies: 1) sputum Xpert MTB/RIF (Xpert); 2) sputum Xpert plus urine AlereLAM (Xpert+

101 als [CI]) were similar to those of Xpert MTB/RIF [sensitivity, 37.5% (25.3 to 51.2) versus 28.6% (15.

102 ymptom-based screening followed by Xpert MTB/RIF [Xpert] testing) is insufficiently sensitive and res

103 M, ELISA a sensitivity of 43%, and Xpert MTB/RIF a sensitivity of 100% and specificities of 87%, 91%,

104 M, ELISA a sensitivity of 38%, and Xpert MTB/RIF a sensitivity of 86% and specificities of 70%, 91%,

105 ata from adults tested for TB with Xpert MTB/RIF across 28 primary health clinics in rural South Afri

106 CSF Xpert MTB/RIF and CSF LAM are highly specific for the diagnosis of

107 aediatric TB comparable to that of Xpert MTB/RIF and interferon gamma release assays.

108 fampicin susceptibility results of Xpert MTB/RIF and mycobacteria growth indicator tube (MGIT) were c

109 fugation, followed by conventional Xpert MTB/RIF and ULTRA.

110 ort of patients with confirmed TB (Xpert MTB/RIF and/or Determine TB-LAM Ag positive) identified thro

111 A prospective cohort of confirmed (Xpert MTB/RIF and/or Determine TB-LAM Ag positive) TB patients ide

112 WHO recommends Xpert MTB/RIF as initial diagnostic testing for tuberculous mening

113 microscopy has been replaced with Xpert MTB/RIF as the initial diagnostic test for tuberculosis.

114 ated the sensitivity analysis with Xpert MTB/RIF as the reference standard.

115 t for TB screening among PWD using Xpert MTB/RIF as the reference standard.

116 a M. tuberculosis assay, the Gene Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA), and a line probe ass

117 Following the endorsement of the Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA, USA) by the World Hea

118 ed per patient and tested with the Xpert MTB/RIF assay (Xpert) and with Lowenstein-Jensen medium (LJ)

119 lification testing (NAAT) with the Xpert MTB/RIF assay (Xpert) may be more efficient and less costly.

120 Xpert MTB/RIF assay (Xpert) on 1, 2, or 3 specimens may be more ef

121 io to perform either point-of-care Xpert MTB/RIF assay (Xpert) or point-of-care light-emitting diode

122 All 1196 individuals received a Xpert MTB/RIF assay and a CXR read by two groups of radiologists a

123 detection of PTB and EPTB by both Xpert MTB/RIF assay and standard conventional methods (culture and

124 sitivity and specificity of of the Xpert MTB/RIF assay compared with microscopy in the diagnosis of p

125 ivity, specificity, PPV and NPV of Xpert MTB/RIF assay counted for 76.5%, 95.9%, 62%, and 97.9% respe

126 assess the diagnostic accuracy of Xpert MTB/RIF assay for both PTB and EPTB.

127 comparison, the sensitivity of the Xpert MTB/RIF assay for molecular detection of M. tuberculosis DNA

128 negative predictive value (NPV) of Xpert MTB/RIF assay for PTB were found to be 95.5%, 96.7%, 83.8%,

129 Diagnostic accuracy of Xpert MTB/RIF assay for pulmonary tuberculosis (PTB) and extrapulm

130 Xpert MTB/RIF assay found to be highly sensitive, specific and com

131 y assessed the practicality of the Xpert MTB/RIF assay in a real-life setting with high prevalence of

132 The Xpert MTB/RIF assay is an automated molecular test that has improv

133 The Xpert MTB/RIF assay is both sensitive and specific as a diagnostic

134 at the quantitative outputs of the Xpert MTB/RIF assay may be useful as a dynamic measure of TB treat

135 sceptibility (MODS) culture or the Xpert MTB/RIF assay might be used to expand bacteriological diagno

136 The Xpert MTB/RIF assay performed well in both HIV-infected and -uninf

137 e positive in 6 eyes, and the Gene Xpert MTB/RIF assay results were positive in 4 eyes.

138 y and very high specificity of the Xpert MTB/RIF assay supports its inclusion in the reference standa

139 y of the Gene drive to that of the Xpert MTB/RIF assay using M. tuberculosiscultures as the reference

140 Mycobacterial culture and Xpert MTB/RIF assay were performed on sputum from children with pe

141 us assay, and in 1 eye by the Gene Xpert MTB/RIF assay.

142 resistance detected by the Cepheid Xpert MTB/RIF assay.

143 cimens were highly variable; thus, Xpert MTB/RIF cannot be recommended to replace standard convention

144 Xpert MTB/RIF cycle threshold values are a measure of sputum mycob

145 f immunosuppression as measured by Xpert MTB/RIF cycle threshold values.

146 pulmonary TB cases, respectively; Xpert MTB/RIF detected 5 additional culture-negative cases.

147 Studies investigating Xpert MTB/RIF diagnostic performance on cerebrospinal fluid (CSF)

148 013, Viet Nam's NTP implemented an Xpert MTB/RIF external quality assurance (EQA) program in collabor

149 Despite the use of Xpert MTB/RIF for diagnostic purpose in real time, TBM was still a

150 the sensitivity and specificity of Xpert MTB/RIF for EPTB specimens were highly variable; thus, Xpert

151 A new TB diagnostic test-Xpert MTB/RIF from Cepheid-was endorsed by the World Health Organi

152 Among TB culture-positive cases, Xpert MTB/RIF had 100% and 81% sensitivity in sputum smear-positiv

153 While molecular tools like Xpert MTB/RIF have advanced our ability to detect Mycobacterium tu

154 We aimed to assess the impact of Xpert MTB/RIF implementation on the delay to treatment initiation

155 ic, yet more costly, tests such as Xpert MTB/RIF in ACF in a high-burden setting?

156 d immunosorbent assay (ELISA), and Xpert MTB/RIF in cerebrospinal fluid (CSF) in an autopsy cohort of

157 y and positive predictive value of Xpert MTB/RIF in culture-negative but clinically diagnosed PTB was

158 g, which raised the sensitivity of Xpert MTB/RIF in detecting rifampicin resistance to 93.8%.

159 Five cases were false-positive by Xpert MTB/RIF in patients with nontuberculous mycobacteria, old PT

160 Xpert MTB/RIF is an effective tool in diagnosing PTB but will be m

161 ting and spinning), LAM ELISA, and Xpert MTB/RIF on the CSF samples.

162 MGIT, MODS and Xpert MTB/RIF on the initial specimen identified 40/51 (78%), 33/5

163 ment, population-level scale-up of Xpert MTB/RIF or microcolony-based culture often averted 10 times

164 104 true positive (culture and/or Xpert MTB/RIF positive) specimens.

165 7 culture-negative specimens were Xpert MTB/RIF positive.

166 excluded, strongly suggesting all Xpert MTB/RIF positives are true positives.

167 Xpert MTB/RIF results for 740 CSF samples from 698 patients across

168 on definite TBM patients when CSF Xpert MTB/RIF results were available in real time to treating phys

169 Patients with positive LAM or Xpert MTB/RIF results were referred for tuberculosis treatment.

170 When Xpert MTB/RIF results were used as the reference standard, sensiti

171 The determinants of Xpert MTB/RIF sensitivity, a widely used PCR test for the diagnosi

172 Xpert MTB/RIF specificity was 100% (99.7-100%) among 1164 specimen

173 randomized to two strategies: (1) Xpert MTB/RIF test (Cepheid, Sunnyvale, CA) performed at a distric

174 The Xpert MTB/RIF test for tuberculosis is being rolled out in many co

175 ict hospital laboratory or (2) POC Xpert MTB/RIF test performed at a primary health care clinic.

176 a 1:1 ratio to undergo screening (Xpert MTB/RIF test, urinary lipoarabinomannan test, and chest radi

177 ially with the introduction of the Xpert MTB/RIF test, used for tuberculosis (TB) diagnosis for all p

178 Sputum samples were collected for Xpert MTB/RIF testing and culture.

179 aims to introduce EQA concepts for Xpert MTB/RIF testing and evaluates five potential EQA panels.

180 ing based on symptom screening and Xpert MTB/RIF testing did not increase the rate of treatment initi

181 ommendation results in unnecessary Xpert MTB/RIF testing in many individuals living in tuberculosis-e

182 TB, using mycobacterial culture or Xpert MTB/RIF testing of sputum, urine, or blood.

183 ings to pre-screen individuals for Xpert MTB/RIF testing.

184 simultaneously provided sputum for Xpert MTB/RIF testing.

185 eened for TB symptoms, and offered Xpert MTB/RIF testing.

186 ad CXRs could reduce the number of Xpert MTB/RIF tests needed by 66% while maintaining sensitivity at

187 rural Malawi, using point-of-care Xpert MTB/RIF to test symptomatic patients for TB at the time of H

188 aluated the diagnostic accuracy of Xpert MTB/RIF Ultra (Ultra) compared to other microbiological test

189 ay tools for pleural TB, including Xpert MTB/RIF Ultra (ULTRA), has hitherto not been comprehensively

190 accuracy and incremental yield of Xpert MTB/RIF Ultra (Ultra; Cepheid), a new rapid test, on repeate

191 diagnostic performance of the new Xpert MTB/RIF Ultra (Xpert Ultra) for tuberculous meningitis.

192 Xpert MTB/RIF Ultra (Xpert Ultra) was developed to overcome this l

193 The Xpert MTB/RIF Ultra assay detects mutations in the rifampin resist

194 udy describes the novel use of the Xpert MTB/RIF Ultra assay for detection of Mycobacterium tuberculo

195 The newer Xpert MTB/RIF Ultra cartridge has shown improved sensitivity in re

196 The sensitivity of MGIT, MODS and Xpert MTB/RIF was 88%, 71% and 76%, respectively, among all 104 tr

197 cility-based screening arm, sputum Xpert MTB/RIF was performed on all patients presenting (for any re

198 We prospectively compared MODS and Xpert MTB/RIF with standard microscopy and culture using the BD MG

199 iologically confirmed cases and 41 Xpert MTB/RIF(R) and culture negative cases.

200 with positive specimens tested by Xpert MTB/RIF) and (2) TBDx alone-against the gold standard liquid

201 ositive urine tests (TB-LAM and/or Xpert MTB/RIF) were associated with increased mortality in multiva

202 ositive urine tests (TB-LAM and/or Xpert MTB/RIF) were associated with increased mortality in multiva

203 us 79.3%; 46 positive cases by the Xpert MTB/RIF), but none from non-TB patients (n = 56).

204 y of the diagnostic tests were CSF Xpert MTB/RIF, 52.9%/94.2%; CSF LAM, 21.9%/94.2%; urine LAM, 24.1%

205 (95% CI, 60.6% to 74.6%); and for Xpert MTB/RIF, 91.0% (95% CI, 85.0% to 94.8%).

206 direct fluorescent AFB smear, SMF, Xpert MTB/RIF, and MGIT culture media.

207 , sputum mycobacterial culture and Xpert MTB/RIF, and nasopharyngeal aspirate multiplex PCR.Measureme

208 ive rapid immunosuspension assay), Xpert MTB/RIF, and ULTRA performance outcomes were evaluated in pl

209 A model including CSF Xpert MTB/RIF, CSF LAM, CSF glucose, and CSF total protein demonst

210 uracy of cerebrospinal fluid (CSF) Xpert MTB/RIF, CSF lipoarabinomannan (LAM), urine LAM, CSF total p

211 ine lipoarabinomannan [LAM], urine Xpert MTB/RIF, or tuberculosis blood culture in 79.6% of deaths ve

212 diagnostic test for tuberculosis, Xpert MTB/RIF, received a conditional programmatic recommendation

213 Xpert MTB/RIF, the first automated molecular test for tuberculosis

214 Xpert MTB/RIF, the most widely used automated nucleic acid amplifi

215 rt, by the success and roll out of Xpert MTB/RIF, there is now considerable interest in new technolog

216 estimated for SMF, AFB smear, and Xpert MTB/RIF, using MGIT as the reference standard.

217 onfidently rule in nor rule out an Xpert MTB/RIF-associated reduction in mortality among outpatients

218 Xpert MTB/RIF-confirmed rifampin-susceptible tuberculosis cases we

219 the composite standard, including Xpert MTB/RIF-positive cases.

220 fugation may increase the yield of Xpert MTB/RIF.

221 aining, mycobacterial culture, and Xpert MTB/RIF.

222 c acid amplification tests such as Xpert MTB/RIF.

223 ested by mycobacterial culture and Xpert MTB/RIF.

224 n patient outcomes associated with Xpert MTB/RIF.

225 um specimens were also examined by Xpert MTB/RIF.

226 ssay performed on a sputum sample (Xpert MTB/RIF; repeated if first result was negative).

227 Notably, nanoformulated RIF and INHP were found to be localized in recycling and

228 Coadministration of nanoformulated RIF and INHP provided a 6-fold increase in therapeutic e

229 By using the RAE as a probe for new RIF-associated genes in several actinomycete genomes, we

230 odal groups, the cathodal group exhibited no RIF.

231 L mutation and two other frequently observed RIF(R) mutants, RpoB D516V and RpoB H526Y.

232 Phi(2)GFP10, in the presence and absence of RIF, and bacilli were enumerated using FACS.

233 functional impact on RNAP in the absence of RIF.

234 While in the case of RIF and PANS-TB, it generated 94.2% and 92.2% sensitivit

235 hia depletion following 7-day combination of RIF+ABZ also led to accelerated macrofilaricidal activit

236 Completion of RIF and RPT/INH for LTBI in an HCW population is more li

237 e images measures the local concentration of RIF in the thin tissue section.

238 Patients receiving standard doses of RIF and INH, who are of the lower range of exposure dist

239 fumarate and lamivudine after initiation of RIF (10 mg/kg/day).

240 Long-acting nanoformulations of RIF and an INH derivative, pentenyl-INH (INHP), were pre

241 ocatalytic activity towards the oxidation of RIF, under the optimal conditions.

242 signature containing 303 genes predictive of RIF.

243 Here, we report a modular total synthesis of RIF-1 stereoisomers and structural analogs.

244 odeficiency virus (HIV)-infected patients on RIF-based antitubercular therapy in the French National

245 At later time points, RIF numbers diminished, along with dropping dose rates,

246 Postinjection RIF counts were significantly higher than baseline value

247 mples shows that the gene signature predicts RIF with 100% positive predictive value (PPV).

248 relations between blood dose and dose rate, RIFs, and platelet counts.

249 Increased occurrence of Rifamycin-resistant (RIF(R) ) TB, approximately 41% of which results from the

250 Results: RIF counts averaged 0.25 +/- 0.15 at baseline.

251 Rifampicin (RIF) induces UGT1A1, an enzyme involved in raltegravir (

252 gnane X receptor (PXR) activator rifampicin (RIF), human hepatocellular carcinoma HepG2-derived ShP51

253 antibiotics isoniazid (INH) and rifampicin (RIF), in an attempt to develop the assay as a screening

254 eatment with isoniazid (INH) and rifampicin (RIF), which affect cytochrome P450 and antiretroviral ex

255 f the natural product antibiotic rifampicin (RIF) to 2'-N-hydroxy-4-oxo-rifampicin, a metabolite with

256 rugs, including front line drugs rifampicin (RIF) and rifabutin (RFB), resulting in altered host defe

257 oniazid (INH), ethambutol (EMB), rifampicin (RIF), pyrazinamide (PZA)], multi-drug resistant TB (MDR-

258 ave developed a tissue model for rifampicin (RIF), an antibiotic used to treat tuberculosis, and have

259 ighly sensitive determination of rifampicin (RIF) by square wave adsorptive stripping voltammetry.

260 t synergized with minocycline or rifampicin (RIF) to deplete symbionts, block embryogenesis, and stop

261 r detection of M. tuberculosis and rifampin (RIF) resistance in sputum.

262 TB) and detect isoniazid (INH) and rifampin (RIF) resistance.

263 B), and detect isoniazid (INH) and rifampin (RIF) resistance.

264 DST (true resistance) was 100% for rifampin (RIF) (14/14), 90.0% for isoniazid (INH) (36/40), 70% for

265 testing (DST) to isoniazid (INH), rifampin (RIF), moxifloxacin (MOX), ofloxacin (OFX), amikacin (AMK

266 d 9-month isoniazid (INH), 4-month rifampin (RIF), weekly rifapentine/isoniazid (RPT/INH) for 12 week

267 1 [V1]) for the rapid detection of rifampin (RIF) and isoniazid (INH) resistance.

268 ly conserved regulatory motif, the rifampin (RIF) -associated element (RAE), which is found upstream

269 ntly associated with patients with rifampin (RIF)-resistant TB.

270 n (PJI), often in combination with rifampin (RIF).

271 Seven major TB drugs (rifampin [RIF], isoniazid [INH], linezolid [LZD], moxifloxacin [MF

272 negative, MTBC-positive (including rifampin [RIF] susceptible and RIF resistant), and nontuberculosis

273 oresistance in 1 patient (0.3%), and INH-S + RIF-S in 220 (68.3%) patients.

274 eptible to rifampicin and isoniazid (INH-S + RIF-S).

275 ociated expression signature also stratifies RIF patients into distinct groups with different subsequ

276 FAD only when RIF is present, implying that RIF binds before NADPH in the catalytic scheme.

277 tion of the expression changes suggests that RIF is primarily associated with reduced cellular prolif

278 The RIF naphthoquinone blocks access to the FAD N5 atom, imp

279 The RIF provided a 2-fold sensitivity increase without signi

280 The RIF was integrated to a SLIM-time of flight (TOF) MS sys

281 The strength of the RIF associated expression signature also stratifies RIF

282 e S531L mutant exhibits a disordering of the RIF binding interface, which effectively reduces the RMP

283 , certainly the electrostatic surface of the RIF binding pocket is dramatically changed, likely resul

284 ing parameters, including RF, DC bias of the RIF electrodes, and electric fields for effectively inte

285 In contrast, the H526Y mutation reshapes the RIF binding pocket, generating significant steric confli

286 Then, RIF was adopted to determine the regulatory impact of ge

287 bitory processes could be causally linked to RIF.

288 applied for the determination of ultra-trace RIF amounts in biological and pharmaceutical samples wit

289 genomes, we identified a heretofore unknown RIF resistance gene, RIF phosphotransferase (rph).

290 NADPH efficiently reduces the FAD only when RIF is present, implying that RIF binds before NADPH in

291 n of FA exposure if used in combination with RIF should be a topic of future research.

292 Compared with RIF counts of (177)Lu-DOTATOC, those of (177)Lu-PSMA wer

293 resolution structure of RIFMO complexed with RIF represents the precatalytic conformation that occurs

294 y used blood dosimetry model correlated with RIF counts, the difference observed in (177)Lu-DOTATOC a

295 with a similar trend during co-culture with RIF.

296 weeks after initiation of RAL together with RIF (period 1), 4 weeks after RIF discontinuation (perio

297 more likely to have completed treatment with RIF (P < .0001) or RPT/INH (P < .0001) than INH.

298 concentration correlated significantly with RIFs at 72 h after injection (Pearson r = -0.34; P < 0.0

299 1 and EMT-like morphological changes without RIF treatment.

300 Chest radiography or Xpert RIF/MTB, delivered through maternal care services, were